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ABSTRACT

Courter, Erik J. L. M.S. Department of Physics, Wright State University, 2016.
Use of ClearView Gel Dosimeter for Quality Assurance and Testing of Stereotactic
Radiosurgery

There exists a lack of accurate, reproducible three-dimensional dosimetry techniques for
stereotactic radiosurgery (SRS) commissioning and quality assurance. This experiment
evaluates the use of ClearView gel dosimeters as an alternative to current methods for
small field dosimetry in SRS testing. ClearView differs from other gel dosimeters in that
it uses tetrazolium salt in its chemical make-up in place of traditional Fricke-type
compounds. Using a Varian TrueBeam radiotherapy system to deliver the radiation, three
vials of ClearView gel dosimeter were tested in three different dose delivery scenarios.
The first test examined the dosimeter’s response to a static beam with the dose isocenter
targeted to the centroid of the vial. The second evaluation consisted of a full rotational
SRS delivery about thecenter of the dosimeter. Lastly, a complete end-to-end treatment
plan was performed to evaluate the accuracy of the dosimeter in a full SRS procedure.
The three dosimeters were then scanned to measure the dose distribution throughout the
gel. Finally, the resulting datawas compared to the initial treatment plan to determine the
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accuracy of the gel. According to the comparisons performed, the ClearView gel showed
capability of sub-millimeter spatial accuracy across the three evaluations, with a
maximum geometric uncertainty of 1.2 mm. Based on these results, ClearView gel
showspromise for possible use in SRS dosimetry applications in clinical settings.
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1.0 INTRODUCTION
Stereotactic radiosurgery (SRS), also known as stereotactic radiotherapy (SRT), is
an increasingly common technique for treating intracranial tumors or other small target
areas. In SRS, high doses of radiation are delivered with very steep falloffs outside of the
target area, saving the healthy tissue surrounding the target [1]. Further advancements in
SRS with rotational delivery allow for even more accuracy and target precision for
treatment of exceedingly small targets [2].On average, typical prescribed doses can range
from 15 – 21 Gy for SRS treatment of cancerous tumors within the brain, with individual
beams of up to 50 Gy [3, 4]. With this high amount of dose being delivered to such
concentrated areas, it is of great importance that the treatment dose be accurately
delivered only to the target area for the safety of the patient.
In order to ensure accurate, safe patient treatmentwith stereotactic radiosurgery, a
quantifiable form of dose measurement is crucial in the commissioning processfor SRS
systems [5]. Commissioning is the first step in determining the viability of a new SRS
system after installation, which examines four basic areas of SRS: precision, localization,
dose distribution, and patient safety [6].A test of precision determines whether or not the
system is able to hit the target area within an established amount of spatial uncertainty
calculated for the machine. Localization can then be verified by ensuring that the dose
delivered to the target does not exceed the target area. Within this area, dose distribution
1

can be examined to determine how the dose of the system would be distributed in human
tissue. Finally, patient safety is carefully monitored throughout the testing procedure to
ensure that no extraneous dose is delivered and outside sources of interference are
limited. After these four properties of a new SRS system have been deemed acceptable
by a Qualified Medical Physicist, the system must then be continually tested to ensure
that the machine stays within the acceptable limits, a process known as Quality
Assurance (QA) [7].
QA tests are essential to SRS systems in order to reduce accidents as well as
identify possible sources of errors in treatments, so the methods to evaluate these systems
must have the capability to examine every aspect of SRS treatment in question [7]. As
stated earlier, SRS systems have the capability to rotate about very small target volumes
during delivery of very high doses. Due to this unique property of SRS treatments, the
resulting dose distribution can become difficult to quantify accurately, requiring an
extensive quality control procedure to ensure SRS accuracy [7, 8, 9, 10].
An integral part of the quality control procedure is the choice of the radiation
detector used for dose determination. Several different types of two-dimensional(2D)
detectors have been utilized for SRS, including ion chambers, radiographic films, and
semiconductor detectors [4, 11, 12, 13]. An overview of the usability and accuracy of
several detector types will be briefly discussed in the following section.
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1.1 Traditional2D Detectors
1.1.1 Ion Chamber
Perhaps the most traditional type of 2Dradiation detector used for SRS dosimetry
is the ionization chamber. Typical ion chambers consist of two electrodes across a
voltage gradient separated by a gas-filled cavity inside the chamber. Incoming ionizing
radiation creates ion pairs within the gas, causing a flow of charge when the charged ions
are accelerated to the oppositely-charged electrodes. This flow of charge can then be
measured to quantify the amount of incoming ionizing radiation.
In the past, ion chamber size has been a limiting factor for SRS applications, with
physical diameters too large for the small field sizes utilized in SRS treatments [8,
14].When the diameter of the detector is comparable to the field size used in SRS
delivery, precise determination of the dose isocenter location can be difficult if even
possible without averaging.However, the development of micro ion chambers has
improved the usability of ion chambers for SRS systems, though averaging can still occur
[4, 15], allowing measurement of dose distribution in smaller fields. Additionally, both
ion chambers and micro ion chambers suffer from a lack of spatial resolution for the high
dose falloffs and intensities required in SRS dosimetry [4, 16].
Finally, another difficulty when using ion chambers for SRS QA is how the beam
interacts with the gas medium inside the ionization chamber itself. Since human tissue is
much more equivalent to water than air, certain ion chambers differ fundamentally in the
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reported dose rate to the dose that would be received by tissue [8]. Therefore, an extra
step must be applied to correct for this difference after the data has been acquired.
1.1.2 Radiographic Film
Another common detector for current SRS QA methods aside from ion chambers
is radiographic film. Basic radiographic film consists of an emulsive layer applied to a
base with a protective coating sealing the emulsion. Though films can differ greatly in
type (single emulsion or double emulsion, intensifying screen or non-intensifying screen),
common films interact with incoming ionizing radiation through the emulsion applied on
the base. Silver halide crystals suspended within the emulsion interact with the incoming
radiation and store the energy until the film is developed. The dose data from the
developed film can then be determined through measuring optical density (OD).
Radiographic films offer much higher spatial resolution than most ion chambers,
which is beneficial due to the steep dose gradients used in SRS treatments [4, 8,
17].However, non-reproducibility is a problem for some applications using radiographic
films [4, 8, 15]. Reproducibility is limited for radiographic films dues to several factors
during manufacturing and exposure to radiation. Films can differ individually due to
inhomogeneities during the manufacturing process, during which crystals in the emulsive
layer are randomly distributed across the film. This distribution can lead to slight
variations in interaction to incoming radiation which in turn leads to different OD
readings after development. Air pockets inside the protective packaging to shield the film
from external light can also cause inhomogeneities in OD readout [15]. Finally, film
orientation in relation to the source also contributes to reproducibility of radiographic
4

films in SRS. Though these limitations can be overcome or simply deemed negligible in
medical imaging procedures, they are too great for consistent use in small field
dosimetry, especially in SRS commissioning and QA.
1.1.3 Semiconductor Detectors
Semiconductors such as diode detectors and metal oxide semiconductor field
effect transmitters (MOSFET) have also been used for SRS dosimetry. Semiconductor
detectors offer small size and can be arranged in arrays for increased spatial resolutions,
and they offer real-time data acquisition [10, 15, 18]. Unfortunately, diode detectors
suffer from temperature dependence and directional dependence in relation to the
source.Also, much like radiographic films, both diode detectors and MOSFETs suffer
from reproducibility issues as well due to orientation in relation to the source [14, 15].
Tissue equivalency is also a disadvantage shown by diodes much like ion chambers [8,
18].
Recently, a new type of semiconductor detector has emerged for SRS dosimetry:
diamond detectors. Developments in production of synthetic diamond have allowed for
the production of small synthetic diamonds for use in dose measurement systems in place
of silicon diodes [10]. Although diamond detectors can be considered soft-tissue
equivalent and energy independent, they have the issue of being dose rate dependent,
requiring calculated corrections to account for this dependence [8, 10].
1.1.4 Thermoluminescent Dosimeters

5

Thermoluminescent dosimeters (TLD) are another radiation detector type used for
dosimetry in clinical applications. This detector type reacts with ionizing radiation by
emitting light proportional to the amount of energy received by the incoming radiation.
TLDs can be created in small sizes and arranged in arrays much like diode detectors,
allowing for a high spatial resolution [19].Some types of TLDs also are largely tissue
equivalent, which allows for closer simulation ofhow dose would be distributed in human
tissue during treatment [14, 18]. The biggest problem with TLDs is that, similarly to both
films and semiconductors, TLDs suffer from issues in reproducibility and consistency[8,
14].
1.2 Gel Dosimeters
All of the above detectors each have individual benefits for use in SRS
commissioning and QA.However, one large drawback to all of the above detectors is
their ability to only capture data in two dimensions.Many detectors, such as ion
chambers, radiographic films, and diodes also are highly dependent on the incoming
beam energy, with films, diodes, and diamond detectors also affected by the rate at which
the dose is being delivered [8, 14, 15]. In addition, some of the above detector types are
limited in the amount of dose that they can measure.
For these reasons, gel dosimetry has emerged as a promising method for ensuring
three-dimensional SRS dose accuracy [9, 11, 20, 21]. The ability to measure dose
delivery in three dimensions allows for precise determination of the isocenter from the
machine’s output. Currently, two main types of gel dosimeters are common for this
purpose, and they will be explored here.
6

1.2.1 Fricke Gel Dosimeters
In 1927, Fricke explored early chemical dosimetry dealing with ferrous-sulphate
solutions for radiation detection [22]. When irradiated, the ferrous Fe2+ ions embedded in
the solution will transform into ferric Fe3+ ions [22]. After the emergence of three
dimensional imaging techniques such as nuclear magnetic resonance imaging (MRI),
Gore proposed further developing Fricke’s techniques to obtain dosimetry for three
dimensional applications [23, 24]. To accomplish this, aqueous Fricke-type solutions
were fused into gels to form three dimensional gel dosimeters, which could then be
scanned by MRI techniques to obtain dosimetry information [25].
In addition to MRI interpreted results, xylenol orange is now commonly added to
the Fricke-typegel solutions as a different data technique. These Fricke-types of
dosimeters will develop a visible color change upon irradiation and subsequent Fe3+ ion
production [26]. This visible color change can then be scanned asOD measurements,
which exhibits a linear relationship with the amount of dose received by the gel [27].
These types of Fricke gels are convenient in that they can be imaged on site at clinics
where MR imagers are not present [24].
Fricke-type gel dosimeters originally suffered from a disadvantage of low
sensitivity, with linear responses up to approximately 10 Gy [25, 27]. However, doses of
up to 40 Gy may result in linear dose relationships if the gel is purged with oxygen prior
to irradiation [28]. This limitation poses a problem for modern SRS techniques, in which
7

higher doses may be delivered during treatment. Additionally, chemical instability of
Fricke gels poses another issue for dosimetry, which causes a degradation of the retained
dose information over time [29]. The diffusion of the Fe3+ ions after irradiation eventually
destroys the spatial resolution contained by the gel [24]. In order to overcome these
limitations, physicists and chemists alike are exploring the development of other types of
gel dosimeters. In addition to the development of polymer gel dosimeters as discussed
below, another type of gel dosimeter based on the chemistry of tetrazolium salts,
ClearView, will be discussed later in section 1.2.3.
1.2.2 Polymer Gel Dosimeters
Another type of common gel dosimeter is a polymer gel dosimeter, which will be
briefly discussed here. Polymer gel dosimeterswere first discussed well after the
emergence of Fricke-type gels. The first step in polymer gel dosimetry occurred in 1957
when works by Andrews examined the effects of ionizing radiation on
polymethylmethacrylate [30]. Following this study, investigations into polymers for
dosimetry showed promise for development of a polymer-type dosimeter.In 1992, a new
type of polymer gel dosimeter under the acronym BANANA emerged, named after its
chemical makeup (bis, acrylamide, nitrous oxide, and agarose) [20]. Later, the agarose
component was replaced with aqueous gelatin under the generic acronym PAG.
Polymer gels exhibit high reproducibility in terms of dose response and
distribution and also have the capability of minimal dose rate dependence [31]. Unlike
Fricke-type dosimeters, these gels use the properties of radiation-induced polymerization
and cross-linking of acrylic monomers and in turn do not suffer from the diffusion
8

problem associated with Fricke gels [11, 20]. However, oxygenation issues posed a
problem for early polymer dosimeters, requiring the dosimeters to be manufactured in an
oxygen free environment. This issue was later remedied by a new formulation of polymer
gels under the acronym MAGIC (methacrylic acid, ascorbic acid, gelatin, and copper),
though limited studies have looked into their use for dosimetry over Fricke-type gels
[20].
1.2.3 ClearView Gel Dosimeter
The dosimeter used in this experiment is ClearView gel dosimeter by Modus
Medical Devices, Inc. (Ontario, Canada). As stated previously, ClearView differs from
other gel-type dosimeters in that it is based on tetrazolium salt chemistry, which was
originally conceived for use in liquids and films. The composition of the gel features less
than one percent of the tetrazolium salt suspended within glycerol (10 vol. %) in water
with a gellan gum gelling agent (1.25 wt. %). This combination of compounds results in a
gel with a physical density of 1.02 g/cm3, which is very close to the density of water.
Due its specific composition, this new type of gel exhibits a strong linear
relationship between absorbed dose and OD of the irradiated gel within ranges of 10-80
Gy. This useful range of linear operation is much wider than the ranges for Fricke-type
gels as discussed in the introduction, giving ClearView a much more flexible use for SRS
treatments. Within this established dose range, higher doses will result in a higher signal
to noise ratio, with an optimal performance range across the middle of the spectrum.
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Upon irradiation, the ClearView gel will exhibit a purple hue proportional to the
dose received, with doses of more than 20 Gy resulting in a change visible to the eye. The
more radiation the gel receives, the darker the shade of purple the gel displays. This color
change is due to the chemical formation of a formazan dye within the gel upon ionization.
Increased radiation absorption correlates directly to an increased formation of the dye,
hence the deepening of the purple shade after more intense irradiation. A manufacturer
recommended development time of 45 minutes after irradiation ensures that the dose
information stored in the dye has time to fully darken in areas where dose has been
concentrated. The development process does not require any additional work by the user,
just that the gel be allowed to remain at room temperature during the 45 minute period as
the chemical reactions in the gel stabilize.
Once irradiated, the purple shade will remain permanently fixed in place within
the gel, thus retaining all of the information regarding dose applied to the dosimeter. Due
to this permanent change, each vial of ClearView gel is designed for a single use. Though
spatially and chemically stable, biological contaminants may form in the gel over time, so
it is best that analysis be conducted within a timely manner after irradiation. Formation of
these contaminants can be limited by keeping the gel in chilled containers during
shipping and storage, though irradiation of the gel should occur after the gel has warmed
to room temperature. The irradiated gel can then be scanned at the manufacturer’s facility
using an opticalcomputed tomography (CT) scanner to interpret the OD values of the gel
and relate them to the amount of ionizing radiation received.
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This experiment will examine several factors of ClearView gel such as its
response to dose delivery and its capability for high spatial resolution in SRS QA. Other
aspects such as energy dependence, dose rate dependence, temperature dependence have
been untested at the time of this experiment, but pose viable options for future research.
2.0 MATERIALS AND METHODS
2.1 Planning
For this experiment, three vials of ClearView gel dosimeter were provided from
Modus Medical Devices, Inc. With these three dosimeters, the goal was to create and
carry out three effective tests to examine the use of ClearView as a clinical gel dosimeter
for commissioning and quality assurance in SRS. After several different possibilities
were examined, three different scenarios were selected to test the gel’s capabilities as an
effective dosimeter.
The first evaluation would serve to test the gel’s accuracy of dose distribution for
a simple, static electron beam targeted through the center of the vial. Since the optimal
range of the gel was centered near 40 Gy as discussed earlier, the plan was to deliver a
total matching isocenter dose of 40 Gy to the first dosimeter. The results of this
irradiation would then show how the dosimeter reacts to dose delivery with minimal
outside factors influencing the irradiation.
The second evaluation of the ClearView gel would expand upon the first
evaluation’s 40 Gy static delivery. However, in this evaluation, the static beam would be
replaced by a rotational delivery technique.As discussed earlier in the introduction, new
11

SRS systems possess the ability to rotate about the target in a 360 degree arc. The
treatment plan would utilize this feature to irradiate the gel in a full rotation about the
second dosimeter to deliver the 40 Gy dose.
With the first two evaluations examining the gel’s performance with basics of
SRS dose delivery, the third evaluation should then examine a more in-depth treatment
plan. To accomplish this, it was decided that a full end-to-end SRS treatment test would
best explore the possibility of using ClearView gel dosimeters for clinical commissioning
and quality assurance. Again, a 40 Gy dose would be delivered for consistency across my
evaluations, though the methods to deliver this dose would shift as needed to account for
the newly-introduced patient geometry and density.
In order to most accurately perform the end-to-end test, it was essential to
simulate the physical make-up of a human patient. To accomplish this, a Phantom
Laboratory, Inc. (Salem, NY) Model TLP290 RSVP Phantom II head phantom was
utilized, which could be filled with water to simulate human tissue for SRS purposes
[32]. With proper positioning, a vial of ClearView at a fixed position within the waterfilled phantom could accurately simulate anintracranial condition. Since intracranial
tumors are commonly treated using SRS systems, it was decided to simulate a left-sided
acoustic neuroma by positioning the dosimeter appropriately within the phantom [33].
2.2 Preparation
Upon receiving 3 vials of ClearView gel from the manufacturer, each of the
sealed vialswas removed from the chilled shipping container and allowed to warm to
12

room temperature. The vials measured 8.5 cm in length and 4.3 cm in diameter, and each
vial had a wall thickness of 1.0 mm.

Figure 2: ClearView gel dosimeter and adapter

Once the vials had warmed to room temperature as required,the acrylic
positioning adapters, which had become disconnected during shipment, were re-attached
tothe top of each vial. To re-attach each acrylic adapter to the jar lids, a quick-dry epoxy
was used aftereach of the adapters was carefully aligned to match with the original
positioning markings on the lid.
2.3 Procedure
2.3.1 Evaluation 1
For the first of the three evaluations, it was decided that a static beam be delivered
through the centroid of one ClearView vial. The jarwas first mounted to a CIVCO
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Medical Solutions (Orange City, IA) 20-CFHN-SUB2 Type-S™ Overlay Board to
prevent movement during the procedure.

Figure 2: CIVCO Type-S™ Overlay Board with attached headrest

Once attached, the board was then placed into a General Electric (Fairfield, CT)
LightSpeed RT CT scanner couch. Initial alignmentof the vial was conducted by
manually aligning the built-in planar positioning lasers to intersect at the visual center of
the vial. Using a 120 kVp scan at 10 mA, a quick “scout” scan was performed to verify
proper placement of the vial. Once positioning was satisfactory, a full helical CT scan of
the headrest at 120 kVp and 350 mA at 1.25 mm increments was performed. A total of
133 images were collected in a time of 46 seconds through a 17.5 mm cone beam.
The imaging data from the CT scan was then sent to the Varian Medical Systems,
Inc. (Palo Alto, CA) Eclipse treatment planning system v11.0. This system allowed for
automatic identification of the scanned object in all three planes: axial, coronal, and
sagittal. Once the appropriate contour of the vial had been identified, the center of the
dosimeter was set to the origin of the planes. Through this central region, a single pencil
beam was assigned to pass through the vial in the Varian Cone Planning software. The
14

beam was designated to be a 6 MV Flattening Filter Free (FFF) beam through a 17.5 mm
cone. A total dose of 40 Gy to the vial isocenterwas planned to be delivered for a beamon time of 4321 MU. The axes of the jar in relation to the beam source are illustrated in
Figure 3 below.

Figure 3: Evaluation 1 ClearView dosimeter axes

Once the treatment planning had been completed, the secured vial was transferred
to the Varian TrueBeam particle accelerator. Again, utilizing three planar lasers to
position the vial, the visual center of the vialwas set at their intersection. A cone of 17.5
mm in diameter was attached to the particle accelerator and placed into the path of the
beam. The room was then cleared, and one static beam was delivered according to the
treatment plan. Upon completion of beam delivery, the vial was removed from the
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overlay board and allowed to develop for 45 minutes as mentioned previously before
being returned to its chilled container.
2.3.2 Evaluation 2
The next evaluation differs fundamentally from the first in that, instead of a single
static beam, two 180 degree arc beams were implemented as discussed earlier. First, the
second ClearView jar was mounted to the CIVCO board in the same fashion as in
Evaluation 1. This assembly was then inserted into the GE LightSpeed CT scanner for
initial imaging. Again, visual alignment of the vial’s center into the intersection of the
three beams’ paths ensured that the dosimeter was properly positioned in the scanner. To
create a treatment plan, the vial was imaged at 120 kVp and 350 mA at 1.25 mm
increments along the length of the jar. As before, a total of 133 images were collected in
a time of 46 seconds through a 17.5 mm cone beam. This data was then networked to the
Varian Eclipse software for treatment planning.
Once in the treatment planning system, the images were again aligned so that the
origin of the three planes was aligned on the center of the ClearView vial. For this
evaluation, two 6 MV FFF beams arcs were programed to rotate around the vial. One
beam was set to rotate clockwise about the jar from 0 to 180 degrees; the other followed a
180 degree rotation from center in the counter-clockwise direction to encompass the vial
entirely between the two beams. Each beam’s path around the dosimeter is shown in the
following illustration.
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Figure 4: Evaluaton 2 ClearView dosimeter axes

These two beams were set to deliver a combined total dose of 40 Gyto the isocenter
through a 15 mm cone. With a successful planning session, the finalized plan was
exported to the TrueBeam console in preparation for delivery.
The 17.5 mm cone from the first evaluation was removed and replaced with a 15
mm diameter cone to match the new treatment plan. The vial assembly was then placed
onto the accelerator’s couch in the path of the visual lasers. Using the intersection of the
three planar beams, the vial was carefully centered under the accelerator. Once the vial
had been aligned properly, the room was cleared, and the treatment plan was
administered. Each of the two arc beams delivered their planned dose for an individual
beam-on time of 2249 MU each. After the beams had delivered their dosage,the vial was
17

detached from the mount, allowed to develop at room temperature for 45 minutes, and
then returned to the chilled container.
2.3.3 Evaluation 3
For the final evaluation, an end-to-end test on the ClearView gel was performed,
making use of a simulated patient geometry and physical density. To accomplish this,
aPhantom Laboratory, Inc. RSVP Phantom II head phantom was utilized, which was
filled with water to simulate human tissue as discussed in the introduction.

Figure 5: Phantom Laboratory head phantom

After filling the phantom with water, preparation of the remaining ClearView gel
dosimeter began. First, three titanium fiducialswere placed around the surface of the jar
for planar identification in the treatment planning software. Then, a plastic rod was
attached at the threaded acrylic adapter. This rod assembly was inserted into the base of
the phantom at the neck. Finally, the dosimeter was positioned within the phantom to
18

simulate the left-sided acoustic neuroma according to the planned procedure. The
phantom was then sealed water-tight to prevent formation of air pockets within the head.
With the dosimeter securely fixed within the phantom, the phantom was attached
to a Varian Head Frame SRS halo through use of four cranial screws. This head frame
allowed secure attachment of the head assembly to the couches of both the CT scanner
and TrueBeam accelerator. Once attached to the CT couch, three additional fiducials
were positioned along the surface of the phantom at the intersections of the wall-mounted
positioning lasers. Now, with a frame of reference for the treatment plan, it was time to
perform the CT scan. At 120 kVp and 350 mA, 149 images were obtained from the
helical scan at 1.25 mm increments in 51.3 seconds. This image set was then sent to the
Eclipse treatment planning software.
Using the two sets of fiducials to align the reference planes, the vial was
contoured, andthe planned dose isocenter was designated to its center. The Cone Planning
software allowed for creation ofa plan of four 6 MV FFF beams delivering a 40 Gy dose
to the ClearView dosimeter isocenter. Using specific gantry rotations in addition to couch
alignment, these beams were programmed to deliver their dose to the pinpoint target of
the vial isocenter with spherical dose falloff. The beam plans are outlined in the
following table using standardized coordinates for table position and gantry rotation [34].
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Beam Table Position Gantry Rotation Beam-on Time
Arc 1

340°

30°-120°

1819 MU

Arc 2

305°

30°-120°

1818 MU

Arc 3

20°

240°-330°

1462 MU

Arc 4

55°

240°-330°

1574 MU

Table 1: Evaluation 3 beam plan

With these four equally weighted beams, the Varian Aria record-and-verify
system performed a cone-beam CT (CBCT) before treatment delivery to ensure
correction of any inaccuracies in phantom alignment on the TrueBeam six-degree of
freedom (6DOF) couch. This treatment plan was finalized and sent to the TrueBeam
console.
The phantom assembly was transferred from the LightSpeed CT scanner to the
TrueBeam 6DOF couch. Using the visual alignment lasers to position the phantom under
the center of the accelerator, the phantom was carefully attached to the 6DOF couch.
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Figure 6: Phantom assembly secured using SRS halo

Again, the 15 mm cone was used to deliver the beams in this evaluation. With the
phantom and ClearView dosimeter in place, the room was cleared in preparation for
treatment delivery.
Once the room was closed, the scheduled 120 kVp CBCT commenced prior to
dose delivery. Using the 6DOF to adjust as necessary, the system corrected for
positioning discrepancies between the treatment plan and the initial placement of the
phantom. After the CBCT had finished and the automatic adjustments were made, each
of the four beams was delivered according to the finalized treatment plan. Once the
treatment was complete, the phantom was removed from the couch and drained. After the
water had been drained, he ClearView gel dosimeter was carefully removed from the
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phantom and dried. Once developed, the dosimeter was placed with the other two vials in
the chilled container.
2.4 Examination
With the three vials securely packed into the chilled shipping container, the
package was then shipped back to the manufacturer for scanning. Two days after initial
treatment delivery, the ClearView vials were scanned at the Modus facility using a Vista
15 optical CT scanner. This OD scan data was then converted to dose distribution using a
calibration scan, which is dependent on manufacturing variation of the gels and thus must
be calibrated for each different batch. This calibrated dose information was then imported
into the VistaView 3D Visualization Software v.0.3.3 where the distribution can be
displayed in three dimensions. Finally, these files were sent back forcomparative analysis
within the VistaView software.
2.5Sources of Uncertainty
For each of the three evaluations, several sources of uncertainty had to be taken
into account. The systematic uncertainties of the evaluations were accounted for in
similar fashion to the studied of AAPM Task Group 42 [R]. For Evaluations 1 and 2, the
first source of uncertainty to appear in the trial was the repositioning of the acrylic
adapter to the lid of the vial. Though the adapter itself was not attached to anything aside
from the lid itself, the markings on the adapter were later used for adjusting scanner
alignment at the manufacturer’s facility. Since the adapter was to be used for this purpose
based on a baseline scan before transit, an attempt to position the 1.0 mm wide markings
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on the adapter itself to directly align with the markings on the vial’s lid was made. Due to
this possible misalignment, an uncertainty contribution of δ1 = 1.0 mm was accredited to
the first evaluations.
The second source of uncertainty taken into account for the first evaluations was
the accuracy of the Varian TrueBeam particle accelerator. A Winston-Lutz isocenter test
was performed to quantify this uncertainty prior to irradiation. On the day of the
evaluations, a 5 cm3 cube with an internally centered fiducial was placed in the 6DOF
couch under the accelerator. This fiducial was then centered under the crosshairs in the
light field of the accelerator at several different orientations. From this test, it was
determined that an additional uncertainty of δ2 = 0.3 mm be included for the gantry
positioning. Another positioning uncertainty that factors into the final results is the
manual alignment of the vial using the wall lasers. Although the placement of the vial
between the CT scanner and the TrueBeam was replicated as uniformly as possible, an
additional alignment uncertainty of δ3 = 0.25 mm was accounted for in the final
uncertainty calculations.
Finally, after the evaluations had been completed, the manufacturer’s reading of
the ClearView gel data introduced additional uncertainties into the results. As stated
previously, small markings on the lids of the vials were scanned prior to shipment to
establish a baseline orientation of the jars within the Vista scanner. When aligning the
small markings, a stated uncertainty of δ4 = 0.5 mm is proposed by the manufacturer. In
addition, the wall of the vial itself contributes a significant amount of uncertainty to the
final results. When scanning the ClearView vial after the dosage has been delivered,
23

several factors can have an effect on the output accuracy. Variables such as wall
thickness, refractive index, and differences in jar manufacturing can all have noticeable
effects on the apparent OD of the gel. With all of these scenarios in mind, a possible
uncertainty of δ5 = 1.0 mm was assigned to the Vista scanner readout.
To calculate the total uncertainty for my data, each of the individual uncertainties
from the five sources listed above was squared. Then, the standard deviation by
quadrature was found by taking the square root of the sum of all the individual squared
uncertainties. This calculation resulted in a total overall uncertainty of δ = 1.6 mm. The
sources and results are shown in the following table.
Uncertainty Source

δ (mm)

Acrylic adapter alignment

1.0

Winston-Lutz isocenter test

0.3

Manual laser alignment

0.25

VistaView scanner alignment

0.5

VistaView scanner readout

1.0

Standard deviation by quadrature

1.6

Table 2: Evaluation 1 and 2 uncertainty sources and values

The sources and values in Table 2 apply only to Evaluations 1 and 2. For
Evaluation 3, several of the sources are replaced according to the method of delivery. As
before, the reattachment of the acrylic adapter introduced an initial uncertainty of δ1 = 1.0
mm when carefully aligning the markers. Since the adapter was used for attachment of
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the vial to the positioning rod in this evaluation, realignment was crucial to obtaining
accurate results.
Unlike Evaluations 1 and 2, Evaluation 3 utilized not only the rotational
positioning of the TrueBeam gantry, but also the movement of the 6DOF couch. With
this additional movement, the Winston-Lutz isocenter test revealed a total uncertainty of
δ2 = 0.6 mm, a 0.3 mm increase over the gantry rotation alone. In place of the manual
laser alignment used to position the vials on the first two evaluations, the onboard CBCT
was utilized in order to align the isocenter of the dose to the centroid of the vial. This
process has a manufacturer specified uncertainty of δ3 = 0.1 mm for the CBCT and 6DOF
couch.
Once again, after the three evaluations had been completed, additional
uncertainties were introduced during the dosimeter scanning process at the manufacture’s
facility. Alignment of the small markings on the top of the vial contributed an alignment
uncertainty of δ4 = 0.5 mm as stated by the manufacturer. Finally, a possible uncertainty
of δ5 = 1.0 mm was assigned again to the Vista scanner readout based on factors of the
physical jar containing the ClearView gel. These sources and uncertainties are listed in
Table 3 below.
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Uncertainty Source

δ (mm)

Acrylic adapter alignment

1.0

Winston-Lutz isocenter test

0.6

CBCT registration

0.1

VistaView scanner alignment

0.5

VistaView scanner readout

1.0

Standard deviation by quadrature

1.6

Table 3: Evaluation 3 uncertainty sources and values

The final standard deviation by quadrature value of δ= 1.6 mm was calculated in the
same fashion as stated for Evaluations 1 and 2.
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3.0 RESULTS
3.1 Preliminary Observations
Immediately after dose delivery, the purple-shaded formazan dye was clearly
visible to the naked eye. As expected, darker shades of purple could be seen closer to the
isocenter of the dose delivery [S]. In Figure 7below, the purple dye can be seen to be
concentrated in the centroid of the vial.

Figure 7: ClearView gel after radiation delivery

3.2Scan Results
3.2.1 Evaluation 1
After receiving the VistaView files from Modus, the scan data was loaded to
compare to the original treatment plan. Using the three reference planes (axial, coronal,
sagittal), thedosimetry results were analyzed in relation to thetreatment plans used for
delivery. For the single beam delivery from Evaluation 1, a side-by-side comparison of
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each plane within the VistaView software shows an early visual compliance between the
two data sets. The brighter red areas correlate to a higher dose received by the gel, where
the blue background indicates a lower or non-substantial amount of radiation.
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.
Figure 8: Evaluation 1 planned (left) and measured (right) dose
distribution by plane. Top to bottom: sagittal (ZY), coronal (ZX), axial (XY)
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From these visual comparisons in Figure 8 above, it is clear that the planned dose
and measured dose show similarities in both shape and intensity. In addition to the
expected dose distribution surrounding the isocenter, slight dose accumulation in the
measured dose planes is visible. However, in order to determine the level accumulated in
the shadowed regions and also verify geometric accuracy, line-dose profiles were used
within the VistaView software across each axis to quantify the results of the dose
distribution. Figures9–11 below show the results.
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Figure 9: Evaluation 2 X-axis line-dose profile across sagittal plane
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Figure 10: Evaluation 1 Y-axis line-dose profile across axial plane
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Figure 11: Evaluation 1 Z-axis line-dose profile across coronal plane
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For these three figures, the red data set represents the measured values obtained
by the ClearView gel through the Vista scanner within its suggested dose range. The blue
data set for each figure shows the planned dose across each axis. The error bars along
each measured data set show the calculated margin of uncertainty (δ=1.6 mm) for each
dose distribution, which was calculated in an earlier section. With the error bars in place,
the dose distribution for the ClearView gel dosimeter falls within the range of acceptable
values for Evaluation 1.
3.2.2 Evaluation 2
The second evaluation was performed to determine the viability of ClearView gel
as consisted of two arc beams delivering equal dosage to the gel. As before, the following
figure shows a side-by-side comparison of the planned dose delivery to that recorded by
the ClearView gel dosimeter.
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Figure 12: Evaluation 2 planned (left) and measured (right) dose
distribution by plane. Top to bottom: sagittal (ZY), coronal (ZX), axial (XY)
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Once again, the above figure shows an early visual indication that the two data
sets share similar shape and intensity relative to one another. The general shapes ofthe
dose distributions between each of the corresponding three planes appear to exhibit the
same falloffs and isocenters, with the measured dose planes again showing slight dose
accumulation outside the targeted region. From these two data sets, three line-dose
profiles were again created for comparison along an axis in each of the three planes.
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Figure 13: Evaluation 2 X-axis line-dose profile across sagittal plane
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Figure 14: Evaluation 2 Y-axis line-dose profile across axial plane
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Figure 15: Evaluation 2 Z-axis line-dose profile across coronal plane
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With the two arc beams, the results from the dosimeter very closely matched the
treatment plan geometrically. As before, the red line represents the ClearView results
within its suggested dose range of 10-80 Gy, and the blue line shows the original
treatment plan. The error bars above represent the calculated margin of uncertainty
(δ=1.6 mm) for each data point along the dosimeter curve.
3.2.3 Evaluation 3
The third and final evaluation of this report examined the use of the ClearView
gel in a full end-to-end SRS treatment. Using the same color-coding as in the previous
two evaluations, I then measured and planned dose distribution were compared between
the two data sets in the VistaView software. Figure 16 below shows the planned dose
planes on the left and the measured dose planes on the right.
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Figure 16: Evaluation 3 planned (left) and measured (right) dose
distribution by plane. Top to bottom: sagittal (ZY), coronal (ZX), axial (XY)

41

The outlines of the jar containing the ClearView gel are purposely present in this
evaluation to show the angled positioning of the jar within the head phantom in relation
to the three reference planes. Within the jar, the dose distribution can be seen to line up
very well, as was the case with both of the previous evaluations. A line-dose profile
across each plane can quantify the data to determine accuracy of delivery. The following
three plots show the dose distribution in this fashion
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Figure 17: Evaluation 3 X-axis line-dose profile across sagittal plane
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Figure 18: Evaluation 3 Y-axis line-dose profile across axial plane
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Figure 19: Evaluation 3 Z-axis line-dose profile across coronal plane
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Figures 17 – 19 show the uncorrected data with uncertainty error bars for each
line-dose profile. Each red line shows the measured results overlaid on top of the blue
planned dose profile.For this evaluation, the uncertainty was determined to be 1.6 mm
along the x-axis of each plot as determined earlier. Though this data does show that the
measured dose distribution almost entirely fits within the acceptable range of error, the
plots can be “corrected” by shifting the measured data sets within the acceptable range of
uncertainty.This correction is not to minimize the visible shifts in data, but only to show
the shapes of the spatial distributions in comparison to the planned profiles. The abscissa
shifts can be seen in Figures 20 – 22 below.
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Figure 20: Evaluation 3 corrected X-axis line-dose profile across sagittal plane
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Figure 21: Evaluation 3 corrected Y-axis line-dose profile across axial plane
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Figure 22: Evaluation 3 corrected Z-axis line-dose profile across coronal plane
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These three plots may be more helpful in comparing the shape of the spatial
distribution of the dose within the gel. Here, the X, Y, and Z axes were shifted by 0.40
mm, 1.2 mm, and -0.50 mm respectively. As noted earlier, the Y-axis seemed to show the
largest shift in data between the planned and experimental distributions, which can be
seen by the first set of line-dose profiles and the required shift in Figure 19. However,
with the dotted red lines representing the data after a maximum of 1.2 mm in abscissa
shift, the shape of each data set is clearly a match with the planned line-dose profile
within the calculated limits of uncertainty.

50

4.0 DISCUSSION
4.1 Spatial Uncertainty
In this experiment, each evaluation’s results fell within the calculated uncertainty
for their respective procedure. The calculation of these uncertainties as discussed in
Section 2.6 closely follow those of AAPM Task Group 42, who determined an achievable
SRS accuracy of 2.4 mm in their report [6]. With a maximum individual uncertainty of
1.6 mm for each evaluation, the results of this evaluation fall well under acceptable limits
for SRS.
For modern SRS treatments, similar calculations are used to determine the
acceptable dose distribution based on three target volumes: gross tumor volume, clinical
target volume, and planned target volume [35]. The gross tumor volume (GTV) is the
extent of the tumor that can be imaged by conventional medical imaging techniques for
treatment planning purposes. Surrounding the GTV is the clinical target volume (CTV),
which not only includes the GTV, but also a localized region surrounding the GTV to
account for the areas of the tumor that cannot be seen through imaging techniques.The
volume encompassed in the CTV is typically a fixed value largely determined by the size
of the GTV and the type of condition.
Lastly, surrounding both the GTV and the CTV is the planned target volume
(PTV). This third volume accounts for uncertainties encountered during treatment
delivery such as tissue movement, delivery tolerances of the equipment used to provide
the treatment, and other geometric sources of uncertainty. In order for successful
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treatment, this volume must be carefully contoured to encompass the entire tumor while
avoiding other structures and healthy tissue that could be adversely affected by treatment.
For the acoustic neuroma condition simulated in this experiment, it is not
uncommon for a 1-2 mm expansion of the PTV surrounding the tumor [36].Based on the
acceptable amount of uncertainty calculated in this experiment, each test showed that the
ClearView gel not only fell within these limits of geometric uncertainty, but also under
the maximum amount typical of actual treatments for this condition. This compliance
between both the experimental and clinical uncertainties shows promise that ClearView
could be well suited for SRS commissioning and QA in terms of spatial resolution and
geometric accuracy.
4.2Accelerator Dose Levels
Prior to the first dose delivery, the dose output accuracy of the TrueBeam
accelerator was verified through several sequential measurements taken with an Exradin
A16 ion chamber (Standard Imaging, Inc. - Middleton, WI) connected to a Capintec, Inc.
(Ramsey, NJ) 192x Digital Dosimeter. From these measurements, the dose output of the
accelerator was verified to have consecutive intensity measurements within 1% of each
other.Throughout the course of the day, the readings are expected to remain within 2% of
the morning test measurements. With the machine performing as expected, the dose
discrepancy between the expected and measured data sets must lie somewhere within the
procedure or the gel itself
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As stated previously, the data used as a baseline for the scanner readings is a
general calibration data set, which may vary from the accelerator used to irradiate the
dosimeter.Gel batch variations also weigh heavily in the calibration data used to
determine the dose received by the gel. Evaluation 3 showed much better response to the
output of the TrueBeam system used in this experiment in comparison to both Evaluation
1 and 2, which showed to vary up to ten percent at the reported isocenter. The change
between the third evaluation and the first two may be a result of batch variation during
chemical gel production. Efforts to reduce batch variation are currently in effect at the
Modus production facility.
Aside from the sources of uncertainty in the gel itself, other possible causes for
the differences in reported dose levels are present. Differences in thickness and
manufacturing of the vial containing the ClearView gelcan slightly affect the OD
readings, which in turn could affect the measured dose level in the gel. Corrections for
vial differences could be implemented once a baseline has been established for the CT
scanner.The scanner can also have its output readings affected by the angle of the
incident light to the curved surface of the vial, causing additional scatter in the OD
measurement process. Again, corrections for these sources of uncertainty are currently
being explored by the manufacturer.
4.3Future Work
Though ClearView gel shows promise of use in SRS commissioning and QA,
further tests could explore other aspects of the gel to ensure that is a suitable replacement
for current methods. Experiments across a wider range of dose delivery techniques could
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show if the gel experiences limitations for SRS QA testing. Although all the tests in this
experiment were performed at the same beam energy for consistency between
evaluations, testing across a wider range of beam energies and dose rates could
demonstrate how the gel reacts in terms of possible energy or dose rate dependence
typical of other dosimetry techniques. In addition, tests across various temperatures could
determine if temperature during irradiation has any significant effects on the measured
output of the gel.
One alternative to relying solely on the ClearView gel dosimeter for not only
spatial distribution but also absolute dose levels received by the gel is to use ClearView
in addition to an output verification device. In this experiment, an Exradin A16 ion
chamber was used prior to gel irradiation to determine the accuracy of the TrueBeam’s
output. Though the ion chamber is poorly suited for SRS dosimetry, the information
obtained from preliminary measurements with an ion chamber could be used to normalize
the dose distribution curve to match the output of the delivery system. Though the
ClearView gel would not be the sole instrument required for SRS commissioning and
QA, it could serve as an integral part of the QA process as a whole. Further testing could
demonstrate the feasibility and effectiveness of this dual-instrumentation approach.

54

5.0 CONCLUSION
In this experiment, new ClearView gel dosimeterswere utilized to measure the
output accuracy of a Varian TrueBeam particle accelerator. To test the dosimeter, three
different evaluationswere performed that encompassed several factors of SRS: one static
beam delivery, one full rotational arc about the central axis, and one full end-to-end SRS
treatment plan simulating the treatment of an acoustic neuroma. The capabilities of the
VistaView softwareallowed for direct comparison of the measured results obtained from
the ClearView gel to the original treatment plans.
Based on the composed line-dose profiles for each of the three evaluations, it
wasverified that the tetrazolium salt-based ClearView gel dosimeter was geometrically
accurate within the calculated window of uncertainty for every evaluation performed in
this project.The sub-millimeter accuracy of the ClearView gel allows precise
determination of the target isocenter after irradiation as well as how much additional dose
is delivered to the surrounding tissue within the steep dose gradients. Though ClearView
shows promise for SRS commissioning and QA due to its high spatial dose distribution in
three dimensions, further testing of reported dose would be needed to verify its use as a
standalone dosimeter for small field dosimetry.
The capability to determine accurately measure spatial dose distribution for these
small-field dose geometries suggests that ClearView could be applied to other treatment
methods employing small-field dosimetry QA. Small-field volumetric modulated arc
therapy (VMAT) and intensity modulated radiation therapy (IMRT) could be appropriate
uses of ClearView gel to determine accuracy during commissioning and QA.
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